# Zalifrelimab

Source: https://onco.cc/drugs/zalifrelimab/  
OnCo record `zalifrelimab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Zalifrelimab is a monoclonal antibody from Nelum Corp, in registered phase 2 trials for pancreatic ductal adenocarcinoma.

## Summary

Zalifrelimab is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Nelum Corp and ImmunoGenesis, in pancreatic ductal adenocarcinoma. A monoclonal antibody: the international non-proprietary name stem -mab marks an antibody that binds one target. The registry record does not state the target unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Monoclonal antibody
- Mechanism: A monoclonal antibody: the international non-proprietary name stem -mab marks an antibody that binds one target. The registry record does not state the target unless named in the trial entries below.

## Sources

- ClinicalTrials.gov: trials of Zalifrelimab: https://clinicaltrials.gov/search?intr=Zalifrelimab

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- trials: [A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab](https://onco.cc/trials/nct06782555/), [Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic C](https://onco.cc/trials/nct04827953/)

---
JSON: https://onco.cc/api/v1/entities/zalifrelimab.json